Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Cancer Health Center

Font Size

FDA OKs New Kidney Cancer Drug

Drug, Called Torisel, Targets Renal Cell Carcinoma
WebMD Health News

May 31, 2007 -- The FDA has approved a new drug called Torisel (temsirolimus) to treat renal cell carcinoma, which is a type of aggressive kidney cancer.

Torisel has been shown to increase patients' survival time, notes Steven Galson, MD, MPH, who directs the FDA's Center for Drug Evaluation and Research.

"We have made significant advances in the battle against kidney cancer. Torisel is the third drug approved for this indication in the past 18 months," says Galson in an FDA news release.

Torisel's maker, Wyeth Pharmaceuticals, says it expects the drug to be available by July.

Torisel inhibits a protein called mTOR that regulates cell production, cell growth, and cell survival.

The FDA approved Torisel based on a clinical trial of 626 patients split into three groups. One group of patients only took Torisel. Another group only took a comparison drug called interferon alpha. Patients in the third group took a combination of Torisel and interferon.

Most patients who only took Torisel lived at least 11 months, compared with 7.3 months for those who only took interferon. That's a difference of about 3.5 months.

In addition, renal cell carcinoma generally took about two months longer to worsen in patients who only received Torisel, compared with those who were only given interferon.

The Torisel-interferon combination didn't significantly improve survival.

The most common adverse reactions, occurring in at least 30% of Torisel-treated patients in the clinical trial, were rash, fatigue, mouth sores, nausea, edema, and loss of appetite.

Renal cell carcinoma, diagnosed in about 51,000 people annually in the U.S., accounts for about 85% of all U.S. adult kidney cancer, according to the FDA.

Today on WebMD

Colorectal cancer cells
New! I AM Not Cancer Facebook Group
Lung cancer xray
See it in pictures, plus read the facts.
sauteed cherry tomatoes
Fight cancer one plate at a time.
Ovarian cancer illustration
Real Cancer Perspectives
Jennifer Goodman Linn self-portrait
what is your cancer risk
colorectal cancer treatment advances
breast cancer overview slideshow
prostate cancer overview
lung cancer overview slideshow
ovarian cancer overview slideshow
Actor Michael Douglas